Cargando…

Toward Overcoming Treatment Failure in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhuqian, Huang, Jie, Xie, Duoli, He, Dongyi, Lu, Aiping, Liang, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732378/
https://www.ncbi.nlm.nih.gov/pubmed/35003068
http://dx.doi.org/10.3389/fimmu.2021.755844
_version_ 1784627574884794368
author Wang, Zhuqian
Huang, Jie
Xie, Duoli
He, Dongyi
Lu, Aiping
Liang, Chao
author_facet Wang, Zhuqian
Huang, Jie
Xie, Duoli
He, Dongyi
Lu, Aiping
Liang, Chao
author_sort Wang, Zhuqian
collection PubMed
description Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA treatment and classified into different categories. Nevertheless, RA treatment is based on a “trial-and-error” approach, and a substantial proportion of patients show failed therapy for each DMARD. Over the past decades, great efforts have been made to overcome treatment failure, including identification of biomarkers, exploration of the reasons for loss of efficacy, development of sequential or combinational DMARDs strategies and approval of new DMARDs. Here, we summarize these efforts, which would provide valuable insights for accurate RA clinical medication. While gratifying, researchers realize that these efforts are still far from enough to recommend specific DMARDs for individual patients. Precision medicine is an emerging medical model that proposes a highly individualized and tailored approach for disease management. In this review, we also discuss the potential of precision medicine for overcoming RA treatment failure, with the introduction of various cutting-edge technologies and big data.
format Online
Article
Text
id pubmed-8732378
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87323782022-01-07 Toward Overcoming Treatment Failure in Rheumatoid Arthritis Wang, Zhuqian Huang, Jie Xie, Duoli He, Dongyi Lu, Aiping Liang, Chao Front Immunol Immunology Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA treatment and classified into different categories. Nevertheless, RA treatment is based on a “trial-and-error” approach, and a substantial proportion of patients show failed therapy for each DMARD. Over the past decades, great efforts have been made to overcome treatment failure, including identification of biomarkers, exploration of the reasons for loss of efficacy, development of sequential or combinational DMARDs strategies and approval of new DMARDs. Here, we summarize these efforts, which would provide valuable insights for accurate RA clinical medication. While gratifying, researchers realize that these efforts are still far from enough to recommend specific DMARDs for individual patients. Precision medicine is an emerging medical model that proposes a highly individualized and tailored approach for disease management. In this review, we also discuss the potential of precision medicine for overcoming RA treatment failure, with the introduction of various cutting-edge technologies and big data. Frontiers Media S.A. 2021-12-23 /pmc/articles/PMC8732378/ /pubmed/35003068 http://dx.doi.org/10.3389/fimmu.2021.755844 Text en Copyright © 2021 Wang, Huang, Xie, He, Lu and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Zhuqian
Huang, Jie
Xie, Duoli
He, Dongyi
Lu, Aiping
Liang, Chao
Toward Overcoming Treatment Failure in Rheumatoid Arthritis
title Toward Overcoming Treatment Failure in Rheumatoid Arthritis
title_full Toward Overcoming Treatment Failure in Rheumatoid Arthritis
title_fullStr Toward Overcoming Treatment Failure in Rheumatoid Arthritis
title_full_unstemmed Toward Overcoming Treatment Failure in Rheumatoid Arthritis
title_short Toward Overcoming Treatment Failure in Rheumatoid Arthritis
title_sort toward overcoming treatment failure in rheumatoid arthritis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732378/
https://www.ncbi.nlm.nih.gov/pubmed/35003068
http://dx.doi.org/10.3389/fimmu.2021.755844
work_keys_str_mv AT wangzhuqian towardovercomingtreatmentfailureinrheumatoidarthritis
AT huangjie towardovercomingtreatmentfailureinrheumatoidarthritis
AT xieduoli towardovercomingtreatmentfailureinrheumatoidarthritis
AT hedongyi towardovercomingtreatmentfailureinrheumatoidarthritis
AT luaiping towardovercomingtreatmentfailureinrheumatoidarthritis
AT liangchao towardovercomingtreatmentfailureinrheumatoidarthritis